{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011201","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.502519+00:00","generated_at":"2026-05-31T11:44:09.783081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aclaris Q2 net loss narrows to $11.0M; cash runway extended into 2028 via $26.5M royalty sale","bullets":["Revenue $2.8M (+47% YoY) driven by higher Lilly royalties; net loss $11.0M vs $29.6M.","Cash, equivalents and securities $149.9M; July 2024 received $26.5M upfront from OLUMIANT royalty sale.","Phase 2a trial of ATI-2138 in atopic dermatitis initiated; enrollment expected in coming weeks.","Seeking global partner for lepzacitinib (ATI-1777) after positive Phase 2b top-line results.","R&D expense fell 65% to $8.8M due to completion of several clinical trials and headcount reductions."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011201","json":"https://secwatch.observer/filing/0001558370-24-011201.json","markdown":"https://secwatch.observer/filing/0001558370-24-011201.md","text":"https://secwatch.observer/filing/0001558370-24-011201.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/0001558370-24-011201-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837024011201/acrs-20240807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:44:09.783081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}